Jackson Square Partners’s Haemonetics HAE Stock Holding History

Jackson Square Partners’s Portfolio HAE Stock Details HAE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q3	–	Sell	-2,298,190	Closed	-$206M	–	90
2020 Q2	$206M	Buy	2,298,190 +500,447	+28%	+$50.5M	1.03%	34
2020 Q1	$179M	Buy	1,797,743 +18,777	+1%	+$2.04M	1.13%	32
2019 Q4	$204M	Buy	1,778,966 +62,115	+4%	+$7.52M	1.07%	34
2019 Q3	$217M	Sell	1,716,851 -238,774	-12%	-$30.3M	1.19%	30
2019 Q2	$235M	Buy	1,955,625 +299,949	+18%	+$29.5M	1.22%	29
2019 Q1	$145M	Buy	1,655,676 +187,950	+13%	+$17.1M	0.79%	35
2018 Q4	$147M	Buy	1,467,726 +28,559	+2%	+$3M	0.9%	31
2018 Q3	$165M	Buy	1,439,167 +194,045	+16%	+$20.1M	0.83%	31
2018 Q2	$112M	Buy	+1,245,122	New	+$105M	0.57%	38

Other funds holding HAE

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Neuberger Berman Group New York $131B AUM 28.36% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Jackson Square Partners's HAE Position: Q3 2020 in Review

Jackson Square Partners sold out of Haemonetics (HAE) in Q3 2020, closing a stake of 2,298,190 shares — an estimated $206M sold.

Jackson Square Partners first reported a position in HAE in Q2 2018 and held it in 9 quarters. The position peaked at $235M in Q2 2019. 268 funds tracked by Wall St. Rank hold HAE as of Q3 2020.

Jackson Square Partners reported no remaining Haemonetics position as of Q3 2020 after selling out during the quarter.
Jackson Square Partners sold 2,298,190 Haemonetics shares in Q3 2020, an estimated $206M.
Jackson Square Partners first reported a position in Haemonetics in Q2 2018 and held it in 9 quarters.
Jackson Square Partners's Haemonetics position peaked at $235M in Q2 2019.
268 funds tracked by Wall St. Rank held Haemonetics as of Q3 2020.

Based on Jackson Square Partners's 13F filing for Q3 2020, filed 13 Nov 2020.